Exploration and Validation of an Advanced Reverse-Phase HPLC Approach for the Concurrent Analysis of Empagliflozin, Linagliptin, and Metformin in Pharmaceutical Dosage Forms
Abstract
A straightforward, precise, and reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for the simultaneous quantification of EMPA, LINA, and MET in pharmaceutical dosage forms. Chromatographic separation was conducted using an Eclipse XDB C18 Column (250 mm × 4.6 mm i.d., particle size 5 \(\mu\)m, maintained at ambient temperature), with a mobile phase consisting of 0.01 N KH2PO4 and acetonitrile in a 50:50 v/v ratio. A pH 5.3 buffer, adjusted with o-phosphoric acid, was utilized. UV detection was carried out at 220 nm, and the retention times were 2.767, 2.362, and 3.276 minutes for EMPA, LINA, and MET, respectively. Calibration plots demonstrated linearity (r2 > 0.999) over the concentration range of 2.5-15 \(\mu\)g/mL for EMPA, 1.25-7.5 \(\mu\)g/mL for LINA, and 250-1500 \(\mu\)g/mL for MET. The method underwent rigorous validation for accuracy, precision, specificity, linearity, and sensitivity. Successfully applied to the quantitative analysis of pharmaceutical dosage forms, the method exhibited no interference from any component of the pharmaceutical dosage form. Validation studies affirmed the specificity, rapidity, reliability, and reproducibility of the method. High recovery and low relative standard deviation further affirmed the method's suitability for the routine determination of EMPA, LINA, and MET in pharmaceutical dosage forms.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.